Related Experiment Video
Updated: Feb 28, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
miRNA-Based Breast Cancer Subtyping Using AHALA Multi-Stage Classification Approach
Mohammed Qaraad1, Eric P Rahrmann1, David Guinovart1
1The Hormel Institute, University of Minnesota, 801 16th Ave NE, Austin, MN 55912, USA.
Background:
Breast cancers are heterogeneous in nature, including many molecular subtypes, each displaying varying characteristics in clinical outcomes as well as in responses to treatments. Subtyping requires absolute precision for the application of precision medicine; however, this is not an easy task, given the dimensionality as well as noise in miRNA expression profiles. Even though miRNAs display potential as a biological marker for subtyping breast cancers, feature selection and optimizing learning algorithms would help harness their potential as a diagnostic tool.
Methods:
We propose the Adaptive Hill Climbing Artificial Lemming Algorithm (AHALA), a hybrid optimization framework that integrates the global search capability of the Artificial Lemming Algorithm with an adaptive hill-climbing local search strategy. Low-variance filtering and differential gene expression analysis were first applied to reduce dimensionality and enhance biological relevance. AHALA was then used to optimize deep neural network hyperparameters for miRNA-based multi-class breast cancer subtype classification. The method was validated using TCGA breast cancer miRNA expression data and benchmarked against state-of-the-art optimization algorithms using the CEC2021 test suite.
Results:
AHALA had a high classification performance measure for each type of breast cancer with a mean accuracy of 95.74%, precision of 95.98%, recall of 95.74%, F1 measure of 95.74%, and AUC value of 0.9682. The new algorithm had superior convergence and significance compared with other optimization algorithms. Feature selection revealed miRNAs that belong to each subtype, such as hsa-miR-190b, hsa-miR-429, hsa-miR-505-3p, hsa-miR-3614-5p, and hsa-miR-935.
Conclusions:
The AHALA framework offers a potent and efficient method of performing miRNA-based subtyping of breast cancer that integrates global exploration and local search to its advantage. Its high level of classification, stability, and ability to identify biologically important biomarkers mark this method as promising.
